Acute respiratory distress syndrome future or investigational therapies

Jump to: navigation, search

Acute respiratory distress syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute respiratory distress syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Mechanical Ventilation Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute respiratory distress syndrome future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute respiratory distress syndrome future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute respiratory distress syndrome future or investigational therapies

CDC on Acute respiratory distress syndrome future or investigational therapies

Acute respiratory distress syndrome future or investigational therapies in the news

Blogs on Acute respiratory distress syndrome future or investigational therapies

Directions to Hospitals Treating Acute respiratory distress syndrome

Risk calculators and risk factors for Acute respiratory distress syndrome future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Brian Shaller, M.D. [2]

Overview

Several medical therapies, including granulocyte macrophage colony stimulating factor (GM-CSF) are currently under investigation as potential treatments for ARDS.

Investigational therapies

Granulocyte macrophage colony stimulating factor (GM-CSF):

  • An observational study found an association between higher levels of GM-CSF in brochoalveolar lavage (BAL) fluid and improved survival in patients with ARDS[1]
  • A study of 6 patients with ARDS due to pneumonia who were administered nebulized GM-CSF demonstrated improvements in lung compliance and mortality scores; 4 of 6 patients survived to discharge[2]

Macrolide antibiotics:

  • An observational study of 47 patients with acute lung injury (ALI) demonstrated an association between administration of macrolide antibiotics and both early discontinuation of mechanical ventilation as well as improved survival at 180 days[3]

References

  1. Matute-Bello G, Liles WC, Radella F, Steinberg KP, Ruzinski JT, Hudson LD; et al. (2000). "Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of acute respiratory distress syndrome". Crit Care Med. 28 (1): 1–7. PMID 10667491.
  2. Herold S, Hoegner K, Vadász I, Gessler T, Wilhelm J, Mayer K; et al. (2014). "Inhaled granulocyte/macrophage colony-stimulating factor as treatment of pneumonia-associated acute respiratory distress syndrome". Am J Respir Crit Care Med. 189 (5): 609–11. doi:10.1164/rccm.201311-2041LE. PMID 24579839.
  3. Walkey AJ, Wiener RS (2012). "Macrolide antibiotics and survival in patients with acute lung injury". Chest. 141 (5): 1153–9. doi:10.1378/chest.11-1908. PMC 3342785. PMID 22116799.

Linked-in.jpg